A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
MediLink Therapeutics (Suzhou) Co., Ltd.
Instituto Nacional de Cancerologia de Mexico
Turning Point Therapeutics, Inc.
Eli Lilly and Company
Chinese University of Hong Kong
George Washington University
VA Office of Research and Development
Revolution Medicines, Inc.
Fundación GECP
Affiliated Hospital of Nantong University
Shanghai Pulmonary Hospital, Shanghai, China
Rutgers, The State University of New Jersey
Fundación GECP
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
The First Affiliated Hospital of Guangzhou Medical University
China Medical University Hospital
Stanford University
Nanfang Hospital, Southern Medical University